Transcriptional Changes Associated with Breast Cancer Occur as Normal Human Mammary Epithelial CellsOvercome Senescence Barriers and Become Immortalized
Molecular Cancer 2007 Volume 6
published by BioMed Central
An Open Access Research article
Research Published 18 January 2007
Abstract (provisional)
Background
Human mammary epithelial cells (HMEC) overcome two well-characterized genetic and epigenetic barriers as they progress from finite primary cells to fully immortalized cell lines in vitro. Finite lifespan HMEC overcome an Rb-mediated stress-associated senescence barrier (stasis), and a stringent, telomere-length dependent, barrier (agonescence or crisis, depending on p53 status). HMEC that have overcome the second senescence barrier are immortalized.
Methods
We have characterized pre-stasis, post-selection (post-stasis, with p16 silenced), and fully immortalized HMEC by transcription profiling and RT-PCR. Four pre-stasis and seven post-selection HMEC samples, along with 10 representatives of fully immortalized breast epithelial cell lines, were profiled using Affymetrix U133A/B chips and compared using both supervised and unsupervised clustering. Datasets were validated by RT-PCR for a select set of genes. Quantitative immunofluorescence was used to assess changes in transcriptional regulators associated with the gene expression changes.
Results
The most dramatic and uniform changes we observed were in a set of about 30 genes that are characterized as a cancer proliferation cluster, which includes genes expressed during mitosis (CDC2, CDC25, MCM2, PLK1) and following DNA damage. The increased expression of these genes was particularly concordant in the fully immortalized lines. Additional changes were observed in IFN-regulated genes in some post-selection and fully immortalized cultures. Nuclear localization was observed for several transcriptional regulators associated with expression of these genes in post-selection and immortalized HMEC, including Rb, Myc, BRCA1, HDAC3 and SP1.
Conclusions
Gene expression profiles and cytological changes in related transcriptional regulators indicate that immortalized HMEC resemble non-invasive breast cancers, such as ductal and lobular carcinomas in situ, and are strikingly distinct from finite-lifespan HMEC, particularly with regard to genes involved in proliferation, cell cycle regulation, chromosome structure and the DNA damage response. The comparison of HMEC profiles with lines harboring oncogenic changes (e.g. overexpression of Her-2neu, loss of p53 expression) identifies genes involved in tissue remodeling as well as proinflamatory cytokines and S100 proteins. Studies on carcinogenesis using immortalized cell lines as starting points or normal controls need to account for the significant pre-existing genetic and epigenetic changes inherent in such lines before results can be broadly interpreted.
Molecular Cancer 2007, 6:7 doi:10.1186/1476-4598-6-7
The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
Hormone replacement therapy does not increase breast cancer recurrence, mortality in survivors
July 20th 2022An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
Read More